MarketLens
Sign Up
Stock AnalysisPro

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

7 months ago
SHARE THIS ON:

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

5 months ago
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

7 months ago
Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

7 months ago
Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

4 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

Stock News•2 weeks ago

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech reported CARVYKTI data showing 50% of RRMM patients remained progression-free and alive five years after a single infusion, with a 69.2% five-year overall survival rate. The results add...
LEGN
Stock News•2 months ago

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers' growth portfolio now accounts for 56% of revenues, led by Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion from legacy drugs.
BMY
Stock News•3 months ago

Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

Bristol Myers Squibb's new drug application for mezigdomide combo therapy was accepted by the FDA for relapsed/refractory multiple myeloma, advancing toward a potential new treatment option.
BMY

Breaking News

View All →
ETFs
AI Chip Demand
Biotech & Pharma
Event-Driven Investing
Expense Ratios
Financial Stocks
Gold & Precious Metals
Healthcare
Management Changes
Pharmaceuticals

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

View More →
Stock News•2 hours ago

Amazon plans $7 billion acquisition of Decart, a fast-growing AI startup

Stock News•3 hours ago

Amazon in Talks to Buy AI Startup Decart for Around $7 Billion

Stock News•4 hours ago

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•6 hours ago

Amazon and Alphabet Just Committed $420 Billion to Data Centers. 1 Stock Is the Better Buy.

Stock News•6 hours ago

3 Quantum Computing Stocks Poised to Outperform IonQ and Rigetti This Month